FreeTrader
عضو محترف
بويوسف انا راح انطره حسب نظريه شمعه بريك اوي
يافلا
يافلا
دورة المؤشرنت للتحليل الفني
50 دينار كويتي
Spex للمضارب صاحب القلب :)
- بادئ الموضوع circle
- تاريخ البدء
FreeTrader
عضو محترف
freetrader قال:بويوسف انا راح انطره حسب نظريه شمعه بريك اوي
يافلا
السهم قاعد ينزل احمر دموي
اذا شم 2.4 انا ببيعها معاه ... هل من صاحب
FreeTrader
عضو محترف
circle قال:
اشوف شي ما تشوفه
سهمك والله قلتلك ما اشتري سهم اخضر
FreeTrader
عضو محترف
circle قال:بو ابراهيم
ياما شرينا سهم حمر وصار ( احمر )
الدم ما يجيب الا دم
سهمك حلو والله يا مشاري ...
بس تدري فيني امخمخ قبل لا ادخل على السهم
وانا مخمخ على كذا سهم وكلهم دشوو بالحظره
دزيتلك امس برايفت لايكون ما شفت
FreeTrader
عضو محترف
freetrader قال:السهم قاعد ينزل احمر دموي
اذا شم 2.4 انا ببيعها معاه ... هل من صاحب
دش الفخ ...........والله كريم
FreeTrader
عضو محترف
الله يخلي البرشوتcircle قال:
FreeTrader
عضو محترف
ما قمت امشي بدونه من رافجت بويوسف ... ساكن يم المغاوير
ابشرك ارتد صاحبنا 2.47
انا ابي اقل شي 3% حسب نظريه بريك اوي
ابشرك ارتد صاحبنا 2.47
انا ابي اقل شي 3% حسب نظريه بريك اوي
Spherix Moves Toward Final Diabetes Trialscircle قال:
Thursday March 23, 11:41 am ET
BELTSVILLE, Md., March 23 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX - News) announced that its CEO, its BioSpherix Division Research Manager, and its consultant, ENVIRON International, Inc., just returned from overseas where they met with key staff members and inspected facilities of a clinical research organization. An agreement for a multi-national Phase 3 clinical trial of Spherix's Naturlose® as a Type 2 diabetes drug is being finalized. Preliminary work is underway and patient recruitment is expected to begin before year-end.
ADVERTISEMENT
Last November, the FDA approved the Phase 1 and Phase 2 clinical trial data submitted by Spherix, and authorized the Phase 3 clinical trial in December (see Spherix's 12/6/05 press release). In January 2006, the Company placed an order with its manufacturer for bulk Naturlose to conduct the trials, and contracted with ENVIRON, a scientific consulting organization highly experienced in FDA regulatory work, to help plan and oversee the trials (see Spherix's 1/10/06 press release). Diabetes is debilitating, widespread, and growing, now affecting more than 18.2 million people in the United States and 170 million people worldwide. Type 2 diabetes is the most common form of the disease.
The protocols for the Phase 3 trials are currently under design. While Spherix is prepared to complete the study on its own, it is investigating possible arrangements with a major drug company should one become interested in the trial. Such a company would be very important to the manufacture, promotion, distribution and sale of the product.
Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on March 3, 1999.
Under its motto, "A World of Solutions," Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in information technology, knowledge management, and biotechnology.
Spherix's Internet address is http://www.spherix.com.
هذا الخبر ونبي المقاومات يا اهل المقاومات
طير والقلب داعيلك
دورة المؤشرنت للتحليل الفني
50 دينار كويتي